Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should vardenafil be used for the treatment of lower urinary tract symptoms associated with BPH?

Nature Clinical Practice Urology volume 5, pages 536–537 (2008)Cite this article

Abstract

This Practice Point commentary discusses the study by Stief and colleagues, and the relationship between lower urinary tract symptoms (LUTS), erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). This randomized, placebo-controlled study analyzed the effects of the phosphodiesterase type 5 inhibitor vardenafil (a treatment for ED) on LUTS related to BPH. Significant improvements in LUTS were observed in patients in the vardenafil group compared with those in the placebo group, and improvements in erectile function and quality of life were reported in both groups. The treatment was well tolerated. The design of this study and the characteristics of the selected study populations were not typical for a BPH study. Consequently, while this study demonstrates that vardenafil is a promising treatment for symptoms secondary to BPH, including LUTS and ED, further studies are needed before phosphodiesterase type 5 inhibitors become a treatment for LUTS associated with BPH.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Berry SJ et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474–479

    Article  CAS  Google Scholar 

  2. McKinlay JB (2000) The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 12 (Suppl 4): S6–S11

    Article  Google Scholar 

  3. Pearlman CK and Kobashi LI (1972) Frequency of intercourse in men. J Urol 107: 298–301

    Article  CAS  Google Scholar 

  4. Braun M et al. (2000) Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 12: 305–311

    Article  CAS  Google Scholar 

  5. Girman CJ et al. (1999) Association of health-related quality of life and benign prostatic enlargement. Eur Urol 35: 277–284

    Article  CAS  Google Scholar 

  6. Rosen R et al. (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44: 637–649

    Article  Google Scholar 

  7. Kaplan SA and Gonzalez RR (2007) Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9: 73–77

    PubMed  PubMed Central  Google Scholar 

  8. Stief CG et al. (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236–1244

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Weill Medical College at Cornell University, 1300 York Avenue, Suite F9 West, Box 261, New York, NY 10065, USA

Authors and Affiliations

  1. and Co-Director of Urodynamics in the Department of Urology at New York Presbyterian Hospital, AE Te is an Associate Professor of Urology at the Weill Medical College at Cornell University, Director of the Brady Prostate Center, New York, NY, USA.,

    Alexis E Te

Authors
  1. Alexis E Te
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Te has declared that he has received grant/research support from, GlaxoSmithKline, Lilly Icos, Pfizer and Sanofi Aventis. He has also been a Consultant for GlaxoSmithKline.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Te, A. Should vardenafil be used for the treatment of lower urinary tract symptoms associated with BPH?. Nat Rev Urol 5, 536–537 (2008). https://doi.org/10.1038/ncpuro1196

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1196

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing